Listen Funding | Overview Active grants and sponsored research Project Date: January 1, 2020 - December 31, 2022Sponsoring Organization: RUNX1 Research Program and Alex's Lemonade Stand Foundation Pharmacologic Enhancement of Residual Wild Type RUNX1 Activity in Familial Platelet Disorder with Propensity to Develop Leukemia (FPD/AML) Description of Major Goals The goal of this study is test the use of src family kinase inhibitors in preclinical models for use in enhancing the residual wild type RUNX1 activity in patients with heterozygous loss-of-function RUNX1 mutations.
Active grants and sponsored research Project Date: January 1, 2020 - December 31, 2022Sponsoring Organization: RUNX1 Research Program and Alex's Lemonade Stand Foundation Pharmacologic Enhancement of Residual Wild Type RUNX1 Activity in Familial Platelet Disorder with Propensity to Develop Leukemia (FPD/AML) Description of Major Goals The goal of this study is test the use of src family kinase inhibitors in preclinical models for use in enhancing the residual wild type RUNX1 activity in patients with heterozygous loss-of-function RUNX1 mutations.
